By Nabil Hanano

Download the PDF

Radical innovations revealing real prospects in health care

A new generation of treatments are paving the way for a golden age in the sector.

November 2024, On the Horizon -

Health care stocks have struggled since the pandemic amid rising costs and falling revenues, but a wave of innovation is transforming the sector’s prospects. A new generation of treatments and technologies are coming to market that deliver radical outcomes, establishing the conditions for what we believe will be a golden age of health care.

The emergence of GLP‑1 drugs targeted at obesity and diabetes has been a seismic development. The investment implications of GLP‑1s are large, not just for the earnings potential of drug developers, but across every part of the health care ecosystem and the wider economy. So far, however, this has not translated into sectorwide outperformance: All health care segments in the S&P 500 have underperformed the broader index over the past two years, and the weighting of the overall health care sector within the index was at its lowest level in 10 years at the end of October (Figure 1). History shows that following periods of declining returns, the weighting of health care within the S&P 500 has typically fallen before recovering.

Health care weighting in S&P 500 is lowest in 10 years

(Fig. 5) All segments in the sector have underperformed the broader index

Next twelve month relative return data end October 31, 2023 and S&P 500 Index data end October 31, 2024. The relative return shown on the y‑axis is that of the healthcare sector within the S&P 500 Index vs. that of the index as a whole.
Past performance is not a reliable indicator of future performance.
Next 12 months are subsequent returns to a given point in time and are not a projection of any return.
Source: Standard & Poor’s, via FactSet (see Additional Disclosures).

Leading GLP‑1 manufacturers have still benefited

Despite declining valuations across health care segments, barriers to entry are high in the GLP‑1 space. The leading manufacturers have gained a competitive advantage by amassing huge amounts of clinical data and building production capacity, and they are also developing next generation drugs that are likely to be better than those currently available. These firms are spending billions of dollars on capital expenditure and research and development in aiming to maintain their dominance.

One of the most important innovations is in small‑molecule GLP‑1s that can be taken in pill form rather than the currently available injection. Due to capacity constraints, there will never be enough injectable drugs to reach the number of people who need them, which means that GLP‑1s in pill form are needed to address the global market in obesity treatments.

The wave of health care innovation is not just limited to GLP‑1s, however. Technological developments are leading to major breakthroughs in areas such as AI‑led cancer screening and robotic surgery, while therapeutic innovations are poised to accelerate demand for companies that sell the necessary bioprocessing production equipment.

Lower rates and inventory normalization should bring timely boost

Rising interest rates in 2022/2023 hit the earnings potential and valuations of biopharma stocks particularly hard. The return to a lower rate environment—and, with that, funding—should be a major boost for the sector. Further support could come from post‑pandemic inventory normalization as the industry returns to more stable demand patterns.

Elsewhere, managed health care organizations are adapting to external cost pressures and technological advances by delivering more value‑based care (where providers are paid based on patient health outcomes) and remote care. They are also increasingly using AI and machine learning to predict patient health outcomes and guide decision‑making.

Investors seeking to benefit from these changes will need to look beyond traditional financial analysis and gain a deeper understanding of the scientific developments underpinning them. For those able to do this, the extraordinary innovation taking place across many health care sectors, combined with the current low valuations available, provide a compelling opportunity.

Key takeaway
A new generation of treatments and technologies are paving the way for what could be a golden age in healthcare.

Key areas of health care development outside of GLP-1s

Nabil Hanano Associate Portfolio Manager, Global Focused Growth Equity Strategy

Nabil Hanano is an associate portfolio manager of the Global Focused Growth Equity Strategy in the U.S. Equity Division. He is an Investment Advisory Committee member of the US Small-Cap Growth Equity, Global Industrials Equity, Europe Equity, and Global Focused Growth Equity Strategies and a vice president of the T. Rowe Price International Funds. Nabil is a vice president of T. Rowe Price Group, Inc., and T. Rowe Price International Ltd.

Nov 2024 • On the Horizon

Weaker growth and lower rates set to open up private markets

By David M. DiPietro

Nov 2024 • On the Horizon

Finding income in high yield bonds, bank loans, and emerging markets

By Kenneth A. Orchard

Sign up to receive our monthly Global Asset Allocation Viewpoints from our Investment Committee

Each month, our Investment Committee prepare a report revealing the two market themes they are watching, their bull and bear views per region and their latest asset class over and underweights.

It has been designed to aid you in your decision making and client conversations.

Adaptive Form Title
First name*
Last name*
Company*
Business email*
Privacy policy
Campaign ID
Product Interest
Submit

First name*

Last name*

Company*

Business email*

By providing your contact information and ticking the box below, you agree to subscribe to receive information from T. Rowe Price about its products and strategies as listed above by email or post. For information about how T. Rowe Price processes your personal data, please see the T. Rowe Price privacy notice.

I agree

Campaign ID

Product Interest

T. Rowe Price cautions that economic estimates and forward‑looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Actual outcomes could differ materially from those anticipated in estimates and forward‑looking statements, and future results could differ materially from any historical performance. The information presented herein is shown for illustrative, informational purposes only. Any historical data used as a basis for this analysis are based on information gathered by T. Rowe Price and from third‑party sources and have not been independently verified.

Forward‑looking statements speak only as of the date they are made, and T. Rowe Price assumes no duty to and does not undertake to update forward‑looking statements.

Where securities are mentioned, the specific securities identified and described are for informational purposes only and do not represent recommendations.

Additional Disclosures

For more information on Third Party Market Data please visit troweprice.com/marketdata.

CFA^® and Chartered Financial Analyst^® are registered trademarks owned by CFA Institute.

Important Information

This material is being furnished for general informational and/or marketing purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice. Prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. Past performance is not a reliable indicator of future performance. The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.

The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources’ accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date written and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request. It is not intended for distribution to retail investors in any jurisdiction.

Australia—Issued by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 28, Governor Phillip Tower, 1 Farrer Place, Sydney NSW 2000, Australia. For Wholesale Clients only.

Canada—Issued in Canada by T. Rowe Price (Canada), Inc. T. Rowe Price (Canada), Inc.’s investment management services are only available to Accredited Investors as defined under National Instrument 45‑106. T. Rowe Price (Canada), Inc. enters into written delegation agreements with affiliates to provide investment management services.

EEA—Unless indicated otherwise this material is issued and approved by T. Rowe Price (Luxembourg) Management S.à r.l. 35 Boulevard du Prince Henri L‑1724 Luxembourg which is authorised and regulated by the Luxembourg Commission de Surveillance du Secteur Financier. For Professional Clients only.

New Zealand—Issued by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 28, Governor Phillip Tower, 1 Farrer Place, Sydney NSW 2000, Australia. No Interests are offered to the public. Accordingly, the Interests may not, directly or indirectly, be offered, sold or delivered in New Zealand, nor may any offering document or advertisement in relation to any offer of the Interests be distributed in New Zealand, other than in circumstances where there is no contravention of the Financial Markets Conduct Act 2013.

Switzerland—Issued in Switzerland by T. Rowe Price (Switzerland) GmbH, Talstrasse 65, 6th Floor, 8001 Zurich, Switzerland. For Qualified Investors only.

UK—This material is issued and approved by T. Rowe Price International Ltd, Warwick Court, 5 Paternoster Square, London EC4M 7DX which is authorised and regulated by the UK Financial Conduct Authority. For Professional Clients only.

USA—Issued in the USA by T. Rowe Price Associates, Inc., 100 East Pratt Street, Baltimore, MD, 21202, which are regulated by the U.S. Securities and Exchange Commission. For Institutional Investors only.

202411‑4019625

Open

Audience for the document: Share Class: Language of the document:

Open Cancel

Download

Share Class: Language of the document:

Download Cancel

Change Details

If you need to change your email address please contact us.

Subscriptions

You are ready to start subscribing.

Get started by going to our products or insights section to follow what you're interested in.

Products Insights

GIPS^® Information

T. Rowe Price ("TRP") claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS standards. T. Rowe Price has been independently verified for the 27-year period ended June 30, 2023, by KPMG LLP. The verification report is available upon request. A firm that claims compliance with the GIPS standards must establish policies and procedures for complying with all the applicable requirements of the GIPS standards. Verification provides assurance on whether the firm’s policies and procedures related to composite and pooled fund maintenance, as well as the calculation, presentation, and distribution of performance, have been designed in compliance with the GIPS standards and have been implemented on a firm-wide basis. Verification does not provide assurance on the accuracy of any specific performance report.

TRP is a U.S. investment management firm with various investment advisers registered with the U.S. Securities and Exchange Commission, the U.K. Financial Conduct Authority, and other regulatory bodies in various countries and holds itself out as such to potential clients for GIPS purposes. TRP further defines itself under GIPS as a discretionary investment manager providing services primarily to institutional clients with regard to various mandates, which include U.S, international, and global strategies but excluding the services of the Private Asset Management group.

A complete list and description of all of the Firm's composites and/or a presentation that adheres to the GIPS® standards are available upon request. Additional information regarding the firm's policies and procedures for calculating and reporting performance results is available upon request.

Other Literature

You have successfully subscribed.

Notify me by email when

regular data and commentary is available
exceptional commentary is available

new articles become available